Surveyed Physicians Report that Invokana Captures a Small Percentage of Patient Share in the Type 2 Diabetes Drug Market, With Significant Increases Expected Six Months from Now Surveyed Endocrinologists Indicate a Higher Mean Interest Level for Tresiba versus Dapagliflozin, According to a New Report from BioTrends Research Group
EXTON, Pa., Oct. 31, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, among surveyed endocrinologists and primary care physicians (PCPs), Janssen Pharmaceuticals' Invokana captures a small percentage of type 2 diabetes patient share, with significant increases expected six months from now. Currently, a majority of type 2 diabetes patients are using metformin (excluding fixed-dose combinations) and one-third of patients are treated with long-acting insulins such as Sanofi's Lantus or Novo Nordisk's Levemir.
The TreatmentTrends®: Type 2 Diabetes (U.S.) 2013 report also finds that, within the GLP-1 drug class, Novo Nordisk's Victoza is the patient share leader, followed by Bristol-Myers Squibb/AstraZeneca's Byetta/Bydureon (if these products are considered independently).
The report examines five products in development for the treatment of type 2 diabetes—Bristol-Myers Squibb/AstraZeneca's dapagliflozin, GlaxoSmithKline's albiglutide, Eli Lilly's dulaglutide, Novo Nordisk's Tresiba and Takeda's fasiglifam. After reviewing a product profile, surveyed endocrinologists indicated a higher mean interest level for the long-acting insulin Tresiba versus the SGLT-2 inhibitor dapagliflozin.
"The report focuses on physician perception of type 2 diabetes product satisfaction, attribute importance, product performance and sales representative frequency and performance," said BioTrends Research Group Director Rob Dubman. "For example, the study found that at least 40 percent of surveyed physicians have seen a sales representative in the past month across 11 products in the survey; however, physicians were more likely to see Novo Nordisk's NovoLog and Merck's Januvia sales representatives in the past month, compared with representatives from Bristol-Myers Squibb/AstraZeneca's Byetta and Onglyza."
TreatmentTrends®: Type 2 Diabetes 2013 is a syndicated report, based on primary market research of 102 U.S. Endocrinologists and 55 U.S. PCPs, which provides a comprehensive view of the current and expected future management of type 2 diabetes patients, which published in October 2013. This report, which is new to the Decision Resources Group portfolio, includes a market overview, referral patterns, patient demographics, current and anticipated patient share, average lines of treatment, number of weeks on therapy, attribute importance and product performance, product satisfaction, sales representative frequency and performance, message recall, statement agreements, future treatment and desirable attributes for new type 2 diabetes treatments, among many other topics.
Members of the media are welcome to attend our upcoming webinar entitled Type 2 Diabetes in the United States—Clinical Practice in a Changing Market Landscape. This webinar will be held on November 19 at 10 a.m. U.S. Eastern Time. For more information, please contact Christopher Comfort at email@example.com.
About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks of their respective holders.
For more information, contact:
Decision Resources Group
SOURCE BioTrends Research Group